[FREE Report] 5 Growth Stocks Under $49
Stay focused on the long-term with these 5 growth stock picks.
Learn More.
Saundra L. Pelletier, insider at Evofem Biosciences
Saundra L. Pelletier Insider Alerts

Get notified the next time Saundra L. Pelletier buys or sells Evofem Biosciences stock. Enter your email address below to get our daily insider buying and selling report.

Saundra L. Pelletier Insider Information

Saundra Pelletier has served as Chief Executive Officer, President and Executive Director of Evofem Biosciences since February 2015. Ms. Pelletier has been responsible for the company’s growth and evolution, and she led Evofem’s transition to the public market in January 2018 (NASDAQ: EVFM).

Ms. Pelletier has assembled an impressive team of seasoned pharmaceutical professionals that have a deep understanding of the women’s healthcare market and what women want, and she attracted new investor capital. She has also led multiple equity financing rounds which have raised over $440 million.

In her more than 25 years of experience in the pharmaceutical industry, Ms. Pelletier has launched pharmaceutical brands worldwide and expanded indications on female healthcare brands in multiple countries. Her experience includes a comprehensive range of women’s healthcare products, cardiovascular, pain management, sleep therapies and medical devices. She has had oversight and accountability for Sales, Marketing, Operations, Medical Affairs, Regulatory Affairs, Manufacturing, Customer Service, Business Development and Strategic Partnerships.

Previously, Ms. Pelletier served as Vice President, Pharmaceuticals at Women First Healthcare, where she raised $40 million in capital. Earlier in her career, Ms. Pelletier served as Corporate Vice President and Global Franchise Leader for G.D. Searle, where she managed a $250 million business unit, managed worldwide partnerships, negotiated cost saving licensing agreements, assessed country infrastructures, developed commercialization plans and hired full scale teams, including contract sales forces.

In March 2020, she joined the Board of Directors for TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer.  She serves as the chair of the Governance/Nomination Committee and is a member of the Audit Committee. She is also a published author, coveted keynote speaker and moderator at key healthcare and political conferences worldwide.

She has appeared at the Harvard School of Public Health, the Davos World Economic Forum, the Clinton Global Initiative, the MAKERS Conference, Women Deliver, the University of Virginia’s Darden School of Business, the University of Oregon’s Lundquist School of Business and the University of California, San Diego.

She is a trained Climate Reality Advocate and hosted a roundtable session at the International Conference on Climate Change, held in Reykjavik, Iceland. Ms. Pelletier has been profiled by The New York Times, Inc. Magazine, Cosmopolitan, Bustle, CNN, Glamour, Marie Claire, and Vogue. She was named as a New Champion for Reproductive Health by the United Nations Foundation, awarded the Athena San Diego’s Pinnacle Award for Life Sciences, named 2019 Business Woman of the Year by the San Diego Business Journal, and named to Inc. Magazine’s 2020 Female Founders 100 List.

What is Saundra L. Pelletier's net worth?

The estimated net worth of Saundra L. Pelletier is at least $415,208.46 as of June 10th, 2021. Ms. Pelletier owns 850,837 shares of Evofem Biosciences stock worth more than $415,208 as of January 20th. This net worth approximation does not reflect any other assets that Ms. Pelletier may own. Learn More.

What is Saundra L. Pelletier's salary?

As the CEO of Evofem Biosciences, Inc., Ms. Pelletier earned a total compensation package of $4,188,344.00 in 2020. Ms. Pelletier earned a salary of $780,850.00, a bonus of $1,045,850.00, stock awards of $1,302,900.00, options awards of $1,044,000.00, and other compensation of $14,744.00.

How do I contact Saundra L. Pelletier?

The corporate mailing address for Ms. Pelletier and other Evofem Biosciences executives is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. Evofem Biosciences can also be reached via phone at (858) 550-1900 and via email at [email protected]

Has Saundra L. Pelletier been buying or selling shares of Evofem Biosciences?

Saundra L. Pelletier has not been actively trading shares of Evofem Biosciences over the course of the past ninety days. Most recently, on Monday, December 20th, Saundra L. Pelletier bought 135,000 shares of Evofem Biosciences stock. The stock was acquired at an average cost of $0.38 per share, with a total value of $51,300.00.

Who are Evofem Biosciences' active insiders?

Evofem Biosciences' insider roster includes Russell Barrans (Insider), Justin File (CFO), Alexander Fitzpatrick (General Counsel), Kim Kamdar (Director), Anthony O'Brien (Director), Saundra Pelletier (CEO), and Lisa Rarick (Director).

Are insiders buying or selling shares of Evofem Biosciences?

In the last year, Evofem Biosciences insiders bought shares 10 times. They purchased a total of 326,414 shares worth more than $212,093.38. The most recent insider tranaction occured on December, 20th when General Counsel Alexander A Fitzpatrick bought 25,000 shares worth more than $9,750.00. Insiders at Evofem Biosciences own 3.9 % of the company.

Information on this page was last updated on 12/20/2021.

Saundra L. Pelletier Insider Trading History at Evofem Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/20/2021Buy135,000$0.38$51,300.00View SEC Filing Icon  
6/10/2021Buy50,000$1.03$51,500.00850,837View SEC Filing Icon  
1/13/2020Sell3,295$6.00$19,770.00362,289View SEC Filing Icon  
1/2/2020Sell6,705$6.05$40,565.25365,584View SEC Filing Icon  
12/2/2019Sell20,000$7.30$146,000.00372,289View SEC Filing Icon  
11/21/2019Sell10,000$6.01$60,100.00424,676View SEC Filing Icon  
8/10/2018Buy10,000$2.11$21,100.00View SEC Filing Icon  
See Full Table

Saundra L. Pelletier Buying and Selling Activity at Evofem Biosciences

This chart shows Saundra L Pelletier's buying and selling at Evofem Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Evofem Biosciences Company Overview

Evofem Biosciences logo
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate) a hormone-free vaginal gel and EVO100 an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $0.49
Low: $0.41
High: $0.51

50 Day Range

MA: $0.44
Low: $0.37
High: $0.67

2 Week Range

Now: $0.49
Low: $0.36
High: $5.53

Volume

12,963,063 shs

Average Volume

8,221,302 shs

Market Capitalization

$79.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Bezos, Elon Musk and Zuckerberg Betting Big on S.C.G.
The "Black Box" Device Bringing the Age of the Smartphone to an End.
Learn More